The time has come to target connective tissue growth factor in diabetic complications
The time has come to target connective tissue growth factor in diabetic complications
复制标题
DOI:
10.1007/s00125-004-1423-6
复制
发表时间:
2004-05
期刊:
影响因子:
8.2
通讯作者:
Stephen M. Twigg;Mark E. Cooper
中科院分区:
文献类型:
--
作者:
Stephen M. Twigg;Mark E. Cooper
leading to the hypothesis that CTGF contributes to early mesangial matrix expansion and the later changes of fibrosis in advanced diabetic nephropathy [10]. ECM expansion is a common feature in tissue affected by diabetes. Indeed, we have recently shown that CTGF is also increased in non-renal tissue. The increases in CTGF correspond with pathological increases in myocardial type III collagen in rodent diabetic cardiomyopathy [11]. In the diabetic apoE-deficient mouse model of atheroma, CTGF mRNA and protein levels are increased in the complex lesions at the fibrous caps, where increases in ECM are also observed [12]. In the eye of the diabetic rodent, CTGF is up-regulated in the ganglion cell layer of the retina [13]. These data suggest that CTGF may contribute to microvascular and macrovascular complications in diabetes.The main metabolic pathways implicated in microvascular complications in diabetes cause an increase in CTGF expression. Depending on the cell type, elevated extracellular glucose, reactive oxygen species, other growth factors implicated in diabetes, eg TGF-β and vascular endothelial growth factor (VEGF)[14],